Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels

Authors

  • Takashi Saika M.D., Ph.D.,

    Corresponding author
    1. Department of Urology, Okayama University Medical School, Okayama, Japan
    • 7675 Phoenix Drive, No. 717, Houston TX, 77030
    Search for more papers by this author
    • Fax: (713) 795-0747

  • Tomoyasu Tsushima M.D., Ph.D.,

    1. Department of Urology, Okayama University Medical School, Okayama, Japan
    Search for more papers by this author
  • Yasutomo Nasu M.D., Ph.D.,

    1. Department of Urology, Okayama University Medical School, Okayama, Japan
    Search for more papers by this author
  • Nobuyuki Kusaka M.D., Ph.D.,

    1. Department of Urology, Okayama University Medical School, Okayama, Japan
    Search for more papers by this author
  • Yoshiyuki Miyaji M.D.,

    1. Department of Urology, National Iwakuni Hospital, Iwakuni, Japan
    Search for more papers by this author
  • Hitoshi Takamoto M.D., Ph.D.,

    1. Department of Urology, Kurashiki Adults Disease Hospital, Kurashiki, Japan
    Search for more papers by this author
  • Katsuji Takeda M.D., Ph.D.,

    1. Department of Urology, Kagawa Prefectural Central Hospital, Takamatsu, Japan
    Search for more papers by this author
  • Satoru Uno M.D., Ph.D.,

    1. Department of Urology, Niihama Juzen Hospital, Niihama, Japan
    Search for more papers by this author
  • Hiromi Kumon M.D., Ph.D.,

    1. Department of Urology, Okayama University Medical School, Okayama, Japan
    Search for more papers by this author
  • for the Okayama Urological Cancer Collaborating Group

    Search for more papers by this author
    • The authors acknowledge the following members of the Okayama Urological Cancer Collaborating Group; Toyoko Yamato, M.D., Ph.D. (Okayama City Hospital); Michinao Saegusa, M.D., Ph.D. (Hiroshima Citizen's Hospital); Toshihiko Asahi, M.D., Ph.D. (Kagawa Prefectural Central Hospital); Bunzo Suyama, M.D., (Mitoyo General Hospital); Tadashi Oeda, M.D., Ph.D. (Onomichi Municipal Hospital); Takanori Murakami, M.D. (National Okayama Hospital); Yoshio Maki, M.D., Ph.D. (Konko Hospital); Teruaki Akaeda, M.D., Ph.D. (Tsuyama Central Hospital); Masatoshi Noda, M.D., Ph.D. (Saint Maria Hospital); Teruhisa Ohashi, M.D., Ph.D. (Okayama Redcross Hospital); and Masahiro Hara, M.D., Ph.D. (Fukuyama Municipal Hospital).


Abstract

BACKGROUND

The authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (PSA) complexed to α-1-antichymotrypsin (PSA-ACT) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (BPH), especially among patients with intermediate PSA levels.

METHODS

Between December 1999 and August 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum PSA levels between 4.1 ng/mL and 20.0 ng/mL. The serum samples were assayed by using kits that were designed specifically for measuring serum PSA, PSA-ACT, and free PSA levels. The clinical values of PSA, PSA-ACT, the free PSA to total PSA ratio (F/T ratio), the free PSA to PSA-ACT ratio, PSA density (PSAD), and PSA-ACT density (ACTD) were compared by using receiver operating characteristic (ROC) curve analysis.

RESULTS

Biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. ROC analysis demonstrated that the area under the curve (AUC) for PSA-ACT was greater than that for total PSA and was equivalent to that for the F/T ratio in both groups of patients (PSA ranges of 4.1–20.0 ng/mL and 4.1–10.0 ng/mL, respectively). The AUC for the ACTD was greater than the AUC for the PSAD and had the highest value of all parameters.

CONCLUSIONS

The measurement of PSA-ACT represents an alternative to the use of total and free PSA. The ACTD value is the most useful for discriminating between BPH and prostate carcinoma. Cancer 2002;94:1685–91. © 2002 American Cancer Society.

DOI 10.1002/cncr.10377

Ancillary